Zhejiang Dayang Biotech Group (003017.SZ): The net income for the first half of the year was 314.363 million yuan, an increase of 31.77% year-on-year.

Gelonghui Finance · Aug 26 09:30

Gelonghui August 26th | Zhejiang Dayang Biotech Group (003017.SZ) released the 2024 interim report, with revenue of 0.437 billion yuan during the reporting period, a decrease of 9.23% year-on-year; net income attributable to shareholders of the listed company was 31.4363 million yuan, an increase of 31.77% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 29.0902 million yuan, an increase of 47.43% year-on-year; basic earnings per share was 0.3857 yuan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

大洋生物(003017.SZ)：上半年净利润3143.63万元 同比增长31.77%

Zhejiang Dayang Biotech Group (003017.SZ): The net income for the first half of the year was 314.363 million yuan, an increase of 31.77% year-on-year.

Risk Disclaimer

Statement

大洋生物(003017.SZ)：上半年净利润3143.63万元同比增长31.77%